The Cost-effectiveness of National Lung Cancer Screening in Türkiye

Basit Öğe Kaydı
dc.authorid0000-0002-6089-1840
dc.authorid0000-0002-7520-760X
dc.authorid0000-0001-9853-4753
dc.authorid0000-0003-3291-8062
dc.authorid0009-0002-5245-8382
dc.contributor.authorMalhan, Simten
dc.contributor.authorGoksel, Tuncay
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorKavakli, Kuthan
dc.contributor.authorSavas, Recep
dc.contributor.authorSendur, Mehmet Ali Nihat
dc.contributor.authorSimsek, Gokcen
dc.date.accessioned2025-02-18T07:48:21Z
dc.date.available2025-02-18T07:48:21Z
dc.date.issued2024
dc.departmentEge Üniversitesi, Tıp Fakültesi, Dahili Bilimler Bölümü, Göğüs Hastalıkları Ana Bilim Dalı
dc.description.abstractOBJECTIVE The aim of this study is to analyze the cost-effectiveness of the national lung cancer screening program in T & uuml;rkiye. METHODS In this cost-effectiveness model, the most likely protocol to be used after implementing a lung cancer survey for T & uuml;rkiye, the NELSON protocol, was used to make a comparison with the "no screening" case. This protocol involves individuals screened using low-dose computed tomography (LDCT). The model is anticipated to simulate 14 screening rounds, assuming an age range of 50-74 for lung cancer and 58 years for the screening program participants. The main outputs of the model were total life years gained (LYG), quality-adjusted life years (QALYs) gained in the screening arm, and the incremental cost-effectiveness ratio (ICER). RESULTS The analyses revealed a total QALY gained in the screening arm of 12,465,801 vs. a QALY gained of 12,149,148 in the comparator no screening arm. The incremental QALY value was estimated to be 316,654. The total LYG were 15,954,511 and 15,370,671 in the screening and no screening arms, respectively, resulting in an incremental LYG of 583,840. With lung cancer screening, stage III and IV cancer were identified in earlier phases in 13,636 cases. Prevented early deaths were 7,576. For the lung cancer screening program, the cost per QALY is $571, and the cost per LYG is $310. CONCLUSION Based on the results, implementation of the national lung cancer screening program was found to be very cost-effective for T & uuml;rkiye.
dc.identifier.citationMALHAN, S., GÖKSEL, T., KARADURMUŞ, N., KAVAKLI, K., SAVAŞ, R., ŞENDUR, M. A. N., & ŞIMŞEK, G. (2025). The Cost-effectiveness of National Lung Cancer Screening in Türkiye. TURKISH JOURNAL OF ONCOLOGY, 1(1).
dc.identifier.doi10.5505/tjo.2024.4464
dc.identifier.endpage13
dc.identifier.issn1300-7467
dc.identifier.issueDec
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.5505/tjo.2024.4464
dc.identifier.urihttps://hdl.handle.net/11454/116075
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.institutionauthorGoksel, Tuncay
dc.institutionauthorSavas, Recep
dc.institutionauthorid0000-0002-6089-1840
dc.language.isoen
dc.publisherKare Publishing
dc.relation.ispartofTurkish Journal of Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectLife year gains
dc.subjectlung cancer
dc.subjectlung cancer screening
dc.subjectNELSON
dc.subjectQALYs
dc.titleThe Cost-effectiveness of National Lung Cancer Screening in Türkiye
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu